Advertisement

Topics

Celgene Corporation and BeiGene, Ltd. Company Profile

02:09 EDT 19th July 2018 | BioPortfolio


News Articles [783 Associated News Articles listed on BioPortfolio]

BeiGene Launches Third Celgene Cancer Drug in China

Beijing's BeiGene has launched Vidaza® in China. Vidaza is a nucleoside metabolic inhibitor that is approved in China for patients with myelodysplastic syndrome (MDS), acute myeloid leukemia (AML)...

China-Kracher BeiGene zündet den Turbo: Neue Zulassung für Celgene-Blockbuster

Es ist die chinesische Biotech-Entdeckung der letzten Monate: BeiGene hat dank des großen Deals mit Celgene auf sich aufmerksam gemacht und eine Rallye von 300 Prozent in den letzten 52 Wochen auf .....

Celgene-Partner BeiGene drückt auf die Tube: Aktie vor Kaufsignal

In China treibt der Celgene-Parner BeiGene die weltweite Entwicklung des Flaggschiffproduktes Tislelizumab weiter voran und befindet sich weiter auf Kurs. Dieser Ansicht sind auch die Analysten der...

BeiGene Completes $750 Million Secondary Offering

BeiGene, a Beijing innovative cancer biotech, raised a spectacular $750 million in a secondary offering of its shares. The price of the shares ended the session 13% higher after the funding was announ...

Nach Highflyer BeiGene: Ist Zai Lab der nächste Biotech-Senkrechtstarter aus China?

Als BeiGene in den USA mit einem erstklassigen Celgene-Deal für Furore sorgte, nutzte Zai Lab, ein anderes chinesisches Biotech-Unternehmen, die Gunst der Stunde, um ein Listing an der US-Tech-Börs....

U.S. Investors Swarm China's Biotech Leader

Depositary shares of the up-and-coming Chinese biotech firm BeiGene jumped 15% today, to $118, after the company successfully raised $750 million in a follow-on share offering. BeiGene has promising d...

BeiGene Initiated Global Phase II Clinical Trial for PD-1 Antibody

BeiGene announced the initiation of a multi-center Phase II clinical trial of tislelizumab, an anti-PD-1 antibody, in patients with previously treated advanced hepatocellular carcinoma (HCC or liver c...

Public ADS offering nets $710.6mm for BeiGene

BeiGene (Beijing) Co. Ltd. (immuno-oncology) netted $710.6mm through the public sale of 7.4mm American Depositary Shares (representing 96.5mm common) priced at $101 per ADS. Proceeds will support gene...

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Clinical Trials [9 Associated Clinical Trials listed on BioPortfolio]

Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult subjects exposed to Gene-modified (GM) T cell therapy participating in a p...

Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003

Multi-center, survival data collection in subjects previously enrolled in Celgene Protocol CC-5013-MDS-003.

A Study to Evaluate Long-term Safety in Subjects With Solid Tumors and Hematological Disorders.

Rollover study supporting solid tumor and hematological disorder indications from Celgene sponsored CC-486 protocols eligible for participation in the study.

Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome

To allow patients with HIV-associated wasting to receive thalidomide treatment at 1 of 2 doses. To gain safety and efficacy data from a broader base of patients with HIV-associated wasting...

Spondylitis Trial of Apremilast for Better Rheumatic Therapy

Presently, there are very few treatments available which affect the progression of the disease in the spine. The only proven treatment is the use of drugs inhibiting tumour necrosis factor...

Companies [197 Associated Companies listed on BioPortfolio]

Celgene Corporation and BeiGene, Ltd.

BeiGene (Beijing), Co., Ltd.

BeiGene is an innovative Chinese oncology R&D company focusing on discovering, developing and commercializing targeted and immune-oncology therapeutics. With a team of 150 scienti...

BeiGene Ltd.

BeiGene is an innovative, clinical-stage Chinese oncology R&D company focused on discovering, developing and commercializing targeted and immune-oncology therapeutics through a no...

BeiGene, Ltd.

BeiGene is a Chinese life sciences biotechnology company based in the Zhongguancun Life Science Park in Beijing that is focused on discovering and developing innovative oncology d...

Celgene International Sàrl

Celgene International Sàrl, located in Boudry, in the Canton of Neuchâtel, Switzerland, is a wholly owned subsidiary and international headquarters of Celgene Corporation. C...

More Information about "Celgene Corporation and BeiGene, Ltd." on BioPortfolio

We have published hundreds of Celgene Corporation and BeiGene, Ltd. news stories on BioPortfolio along with dozens of Celgene Corporation and BeiGene, Ltd. Clinical Trials and PubMed Articles about Celgene Corporation and BeiGene, Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Celgene Corporation and BeiGene, Ltd. Companies in our database. You can also find out about relevant Celgene Corporation and BeiGene, Ltd. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record